Drug Database
MO

mosapride + rebamipide (MotiReb / Mucosta + Gasmotin / MR tablet)

✓ Approved

Ildong Pharmaceutical · HTR3A · 小分子

什么是 mosapride + rebamipide?

mosapride + rebamipide 是一种小分子,由Ildong Pharmaceutical研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名MotiReb, Mucosta + Gasmotin, MR tablet
公司Ildong Pharmaceutical
药物类别小分子
分子靶点HTR3A, HTR4
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

mosapride + rebamipide 作用于 2 个分子靶点:

HTR3A5-hydroxytryptamine receptor 3A (5-HT3R, 5-HT-3)
HTR45-hydroxytryptamine receptor 4 (5-HT4, 5-HT4R)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

mosapride + rebamipide 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Gastrointestinal disordersDyspepsia✓ Approved

相关研究文献

PubMedOral diseases2026-11-06

Systemic Therapies for Recurrent Aphthous Stomatitis: A Systematic Review of Efficacy and Safety.

Sánchez Sáez Gema G, Gómez García Francisco José FJ, Ruíz Roca Juan Antonio JA, Galera Molero Fe F

To evaluate the efficacy and safety of systemic pharmacological and nutritional interventions for recurrent aphthous stomatitis (RAS). Following PRISMA 2020, five databases were searched for studies published from 2001 to 2026. Clinical trials and analytical observational studies of systemic treatments for RAS were included. Risk of bias was assessed using design-appropriate tools. Owing to clinical and methodological heterogeneity, findings were synthesized qualitatively. Twenty studies were included: 16 randomized trials, three non-randomized intervention studies, and one observational cohort. Interventions included corticosteroids, colchicine, thalidomide, levamisole, pentoxifylline, dapsone, clofazimine, sulodexide, montelukast, roflumilast, rebamipide, vitamin B12, vitamin C, multivitamins, zinc, and omega-3 fatty acids. Several therapies improved pain, ulcer burden, healing, or recurrence-related outcomes, but comparative evidence was inconsistent. Thalidomide showed potential benefit but important safety limitations and a high risk of bias. Nutritional interventions showed mixed results. Selected systemic therapies may benefit severe, frequent, or refractory RAS, but no intervention can be considered clearly superior. Evidence certainty is limited by heterogeneity, small samples, limited direct comparisons, and risk of bias.

PMID 42989707
阅读全文 →
PubMedNeurogastroenterology and motility2026-11-05

Pyeongwi-San, a Traditional Digestant, Mitigates Proton Pump Inhibitor-Induced Dyspepsia Through Gut Microbial and Cholinergic Mechanisms in Mice.

Wang Jing-Hua JH, Han Song-Yi SY, Lee Kyung Jae KJ, Lim Mi Young MY et al.

Long-term use of proton pump inhibitors (PPIs) is frequently associated with gastrointestinal (GI) side effects, including dyspepsia, mediated through alterations in gastric pH, impaired GI motility, and gut microbiota dysbiosis. Traditional East Asian herbal formulas-Pyeongwi-san (PS), Yijung-tang (YT), and Shihosogan-tang (ST)-have long been employed clinically for GI disorders; however, their comparative efficacy and mechanistic profiles in PPI-induced GI dysfunction remain undefined. This study aimed to compare the therapeutic efficacy and underlying mechanisms of PS, YT, and ST in a murine model of PPI-induced GI dysfunction, with particular focus on motility, mucosal integrity, gut microbiota modulation, and relevant biomarker responses. Male C57BL/6 mice received oral esomeprazole (160 mg/kg/day) for 4 weeks to induce dyspeptic symptoms. Concurrently, animals were administered PS, YT, or ST (1 g/kg/day), or mosapride (3 mg/kg/day) as a positive control. Outcome measures included gastric acid secretion, intragastric pH, GI motility (gastric emptying and intestinal transit), mucosal histopathology, serum and intestinal hormone levels (secretin, acetylcholine), fecal short-chain fatty acid (butyrate) concentrations, gut microbiota composition (diversity indices and taxonomic profiling), mucosal barrier gene expression (MUC2, ZO-1, Occludin), proinflammatory cytokines (IL-1β, TNF-α), and H+/K+-ATPase protein expression. Esomeprazole reliably suppressed gastric acid secretion, elevated intragastric pH, impaired GI motility, induced mucosal injury, and caused gut microbiota dysbiosis. Among the three herbal formulas tested, PS showed significant improvements across a broader range of measured endpoints relative to the PPI group. PS significantly improved gastric emptying and intestinal transit times (p < 0.05 vs. PPI group), whereas mosapride improved gastric emptying but showed no significant effect on intestinal transit. It further elevated serum secretin, intestinal acetylcholine, and fecal butyrate levels (p < 0.05 vs. PPI group); restored gut microbiota alpha-diversity; and upregulated mucosal barrier genes. PS also suppressed proinflammatory cytokine expression and modulated H+/K+-ATPase protein expression, indicative of integrated gastroprotective and prokinetic mechanisms. YT and ST also showed significant effects on selected endpoints. PS most effectively attenuated PPI-induced GI dysfunction through a multi-target mechanism encompassing prokinetic activity, gut microbiota restoration, mucosal barrier reinforcement, and immunomodulatory regulation of key hormones and cytokines. These findings position PS as a promising botanical candidate for the management of PPI-related dyspepsia, warranting further investigation in controlled clinical trials.

PMID 42983198
阅读全文 →
PubMedInternational journal of nanomedicine2026-11-04

3D-Printed Rebamipide Nanocrystal Oral Thin Films for Gastroprotection Against Indomethacin-Induced Gastric Lesions in Arthritic Rats.

Otake Hiroko H, Azuma Riku R, Ogata Fumihiko F, Nakazawa Yosuke Y et al.

Gastric mucosal injury caused by long-term nonsteroidal anti-inflammatory drug therapy remains a significant clinical concern, particularly in patients with rheumatoid arthritis. In this study, we developed a three-dimensional (3D)-printed oral thin film (OTF) formulation incorporating rebamipide (REB) nanocrystals (REB-NP@OTF) with enhanced gastroprotective potential. REB nanocrystals were prepared by wet bead milling using methylcellulose and hydroxypropyl-β-cyclodextrin as stabilizers. The nanocrystals were incorporated into a polymeric OTF matrix using semi-solid extrusion-based 3D printing. Particle size was measured by nanoparticle tracking analysis using a NanoSight LM10 system, and in vitro drug release was compared with that from OTF containing micro-sized REB (REB@OTF). Gastric mucosal drug retention was evaluated using rats, and therapeutic efficacy was assessed in an indomethacin (IND)-induced gastric injury model using adjuvant-induced arthritis (AA) rats. REB nanocrystals had a mean particle size of approximately 114 nm. Compared with REB@OTF, REB-NP@OTF exhibited a smoother and more uniform internal structure with densely packed particles. Both formulations satisfied the pharmacopeial criteria for weight and content uniformity; however, nanocrystal incorporation significantly altered the pharmaceutical properties. Compared to REB@OTF, REB-NP@OTF showed a 4.2-fold increase in solubility, enhanced hydration behavior, and faster drug release under simulated intestinal conditions. Importantly, particle size analysis confirmed that REB was released from REB-NP@OTF while maintaining its nanoparticulate state. In vivo studies revealed prolonged gastric mucosal retention following oral administration of REB-NP@OTF. In an IND-induced gastric acute injury model using AA rats, REB-NP@OTF markedly reduced the gastric lesion area relative to the REB@OTF containing conventional REB powder. These findings indicate that 3D-printed REB nanocrystal OTFs represent a promising and versatile strategy for improving gastroprotective therapy.

PMID 42979241
阅读全文 →
PubMedFrontiers in neuroscience2026-11-04

Automated temporal analysis reveals stress-induced protracted feeding regulated by mesolimbic dopamine in mice.

Guo Xiaokai X, Fujioka Yusuke Y, Kawai Kaori K, Ishigaki Shinsuke S

Feeding behavior is altered in neuropsychiatric disorders, and environmental stressors also shape it. In our previous study, mice exposed to multiple stressors developed feeding behavior patterns characterized by a deviated bait approach, which we defined as "fixated feeding," together with impairment of the mesolimbic dopamine system. Here we examined the temporal organization of feeding behavior using an AI-based analytical framework built on DeepLabCut and SimBA. Mice subjected to social isolation or intermittent high-fat diet (HFD) exposure showed prolonged feeding bouts, a pattern we define as "protracted feeding." Dopamine administration into the nucleus accumbens (NAcc) shell attenuated diet- and isolation-induced protracted feeding. Physical restraint stress alone did not induce protracted feeding, but mosapride treatment prolonged feeding bouts in restrained mice. Restraint-associated peripheral autonomic and gastrointestinal states may therefore influence the expression of stress-related temporal feeding deviations. In the VTA-DREADD cohort, the same temporal analysis showed that inhibition of VTA dopaminergic activity prolonged feeding bouts. This extends the fixated-feeding circuit framework from the spatial to the temporal domain. These deviations were not consistently accompanied by changes in the amount consumed or in metabolic factors, so alterations in temporal feeding patterns may reflect perturbation of a stress-associated pathway in the mesolimbic dopamine system. Protracted feeding, together with fixated feeding, may serve as a candidate behavioral readout of stress-associated reward-system dysfunction.

PMID 42978662
阅读全文 →
PubMedFrontiers in medicine2026-10-30

Tianwang Buxin Dan regulated PI3K/Akt/mTOR signaling pathway to improve constipation and emotional disorders in rats.

Wang Heng H, Li Xinran X, Chen Zhaoyu Z, Ji Li L et al.

Functional constipation (FC) is frequently comorbid with anxiety and depression, yet pharmacological strategies targeting both gastrointestinal and emotional symptoms remain limited. This study investigated the therapeutic effects and molecular mechanisms of Tianwang Buxin Dan (TWBXD), a classical Chinese herbal formula, in treating FC with emotional disturbances using an integrated strategy combining network pharmacology, molecular docking, and in vivo validation. TWBXD chemical constituents were characterized exclusively by UHPLC-MS/MS, yielding 650 compounds for network pharmacology. Targets were predicted via TargetNet and intersected with disease-associated genes from GeneCards. Common targets underwent PPI network analysis, GO/KEGG enrichment, and molecular docking. In vivo, a rat model was established by CUMS plus diphenoxylate and treated with TWBXD (low, medium, high doses) or positive drugs (mosapride plus fluoxetine) for 28 days. Therapeutic effects and pathway regulation in colon and hippocampus were evaluated by behavioral tests, gastrointestinal function assessment, histopathology, transmission electron microscopy, Western blotting, and qPCR. Network pharmacology identified 473 drug targets and 308 disease-overlapping targets. KEGG enrichment highlighted PI3K-Akt, MAPK, IL-17, and neuroactive ligand-receptor interaction pathways, while PPI analysis identified Akt1, IL-6, and TNF as hub genes. Molecular docking showed quercetin, luteolin, and tanshinone IIA bound stably to Akt1, IL-6, and JUN (binding energies ≤ -6.6 kcal/mol). In vivo, TWBXD dose-dependently improved fecal water content, intestinal transit, sucrose preference, and open-field performance, and attenuated colonic mucosal injury, hippocampal neuronal damage, and mitochondrial disruption. Mechanistically, TWBXD was associated with increased PI3K/Akt/mTOR phosphorylation in colonic and hippocampal tissues and with reduced JNK expression in the hippocampus. No organ toxicity was observed. TWBXD alleviates constipation-related gastrointestinal dysfunction and comorbid anxiety/depression-like behaviors in rats, and these effects are associated with activation of PI3K/Akt/mTOR signaling in colonic and hippocampal tissues and with modulation of JNK signaling in the hippocampus. Although the concordance between computational predictions and multi-level in vivo validation supports TWBXD as a multi-target therapeutic candidate for functional constipation with emotional comorbidities, the causal contribution of PI3K/Akt/mTOR signaling, and the extent to which the peripheral and central changes are functionally coupled through the gut-brain axis, remain to be established.

PMID 42959489
阅读全文 →
PubMedClinical ophthalmology (Auckland, N.Z.)2026-10-27

Long-Term Safety and Clinical Outcomes of Motugivatrep (SJP-0132) 0.3% Ophthalmic Suspension in Patients with Dry Eye Disease: An Open-Label, Phase 3 Study.

Hori Yuichi Y, Wada Tomoyuki T, Omatsu Kazunori K, SJP-0132 study group et al.

To evaluate the long-term safety and clinical outcomes of motugivatrep (SJP-0132) 0.3% ophthalmic suspension in patients with dry eye disease (DED). In this open-label, multicenter, 52-week Phase 3 study, patients aged ≥18 years with a ≥6-month history of DED, at least one question scored ≥1 on the Dry Eye-related Quality-of-Life Score questionnaire, eye dryness Visual Analog Scale score ≥40, 5-item Dry Eye Questionnaire score ≥6, and tear break-up time ≤5 seconds received motugivatrep 0.3% (1 drop/eye) four times daily for 52 weeks, as monotherapy or in combination with diquafosol sodium, rebamipide, or sodium hyaluronate. Primary endpoints were the incidence and severity of treatment-emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs). In the safety analysis set (n=162; monotherapy, n=105; combination, n=57), TEAEs occurred in 45.1% of patients overall (monotherapy 39.0%, combination 56.1%), and TRAEs in 14.8% overall (12.4%, 19.3%). All TRAEs were mild except for three moderate nonocular events in a single patient receiving combination therapy; these recovered/resolved without additional medication after treatment discontinuation. The most common ocular and nonocular TRAEs were eye discharge (3.1%) and feeling cold (7.4%), which also recovered/resolved. Changes from baseline were generally favorable across subjective symptom measures and objective signs, regardless of monotherapy or combination therapy. Motugivatrep 0.3% ophthalmic suspension, as monotherapy or in combination, was well tolerated over 52 weeks, with improvements in both symptoms and signs of DED maintained throughout treatment.

PMID 42936767
阅读全文 →

注册免费账户还可查看另外 1137 篇文献

免费注册查看全部文献 →

了解更多mosapride + rebamipide